MedTrace Logo

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines

NCT01189747 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 446

Last updated 2019-05-07

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthal Rhytides).

Conditions

  • Lateral Canthus Rhytides
  • Crow's Feet Lines

Interventions

BIOLOGICAL

onabotulinumtoxinA

24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1

DRUG

normal saline

Injected into bilateral Crow's Feet Line areas on Day 1

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-01
Primary Completion
2011-04-01
Completion
2011-07-01

Countries

  • United States
  • Belgium
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01189747 on ClinicalTrials.gov